| Name | Title | Contact Details |
|---|---|---|
Karen Walker |
Chief Technology Officer | Profile |
The focus of Regen BioPharma, Inc. is to developing translational medicine platforms for the rapid commercialization of stem cell therapies and to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the purpose of increased quality of life. Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale.
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity`s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature`s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.
OpGen, Inc. is a leading innovator in rapid, accurate genomic and DNA analysis systems and services.
Asklepios BioPharmaceutical, Inc. (AskBio) is a leading clinical-stage adeno-associated virus (AAV) gene therapy company dedicated to improving the lives of patients with rare diseases and other genetic disorders.
Cibus is part of the multi-billion-dollar plant seed industry. Cibus leads the new era of high throughput gene editing technology that can develop plant traits precisely at a fraction of the time and cost of conventional breeding. Cibus is not a seed company. We are a technology company that uses gene editing to develop plant traits. Cibus licenses its traits to seed companies for royalties on seeds that use its traits. Cibus` target market is Productivity Traits” that improve yields, lower input costs such as chemicals and increase the sustainability and profitability of farming. We has a pipeline of six productivity traits including traits for pod shatter reduction, disease resistance and nutrient use efficiency. Cibus` focus is multi-crop traits for the major crops: canola, rice, soybean, wheat, and corn. In other words, traits that can impact global agriculture sustainability at scale. Technology: Gene editing in agriculture is a plant breeding technology. The promise of gene editing in agriculture is the ability to develop plant traits that are indistinguishable from traits developed using conventional breeding but can be developed at a fraction of the time and cost. To many, gene editing represents agriculture`s “analog to digital” technology moment. It is a technology that changes the speed and scale of trait development. Cibus is at the forefront of this technology moment. Our Rapid Trait Development System™ (RTDS®) and Trait Machine™ process represents the first end-to-end semi-automated plant breeding system. Vision: Cibus` vision is to be a pure play trait developer; a technology company whose business is to develop and license plant traits to seed companies in exchange for royalties. The licensing of plant traits and germplasm with quantifiable benefits and strong intellectual property is an integral part of the seed industry. Our goal is to be a leader in this segment of the seed industry.